Table 3.

Univariate analyses of CCL5, ER-α, ER-β, PR, and ErbB2 expression in breast cancer patients using Cox proportional hazard models

PHR95% limits
Stage I
    CCL50.90861.0460.489, 2.237
    ER-α0.63110.8310.389, 1.772
    ER-β0.67450.8140.312, 2.126
    PR0.50440.7720.362, 1.648
    ErbB20.05632.1230.980, 4.599
    CCL5+/ErbB2+0.38561.4960.602, 3.715
Stage II
    CCL50.00452.2181.280, 3.844
    ER-α0.00410.4580.269, 0.780
    ER-β0.91560.9710.568, 1.661
    PR0.01070.4990.292, 0.851
    ErbB20.23071.4410.793, 2.618
    CCL5+/ER-α0.00013.4551.838, 6.491
    CCL5+/PR0.02532.0161.091, 3.727
    CCL5+/ErbB2+0.01402.3101.184, 4.506
    CCL5/ER-α+0.00290.3870.207, 0.722
    CCL5/PR+0.00050.2770.135, 0.569
Stage IIA
    CCL50.06101.9820.969, 4.055
    ER-α0.03150.4700.236, 0.935
    PR0.02600.4580.230, 0.910
    CCL5+/ER-α0.00035.6802.203, 14.64
    CCL5+/PR0.05232.4250.991, 5.932
    CCL5/ER-α+0.04880.4810.233, 0.996
    CCL5/PR+0.00920.3450.155, 0.769
Stage IIB
    CCL50.17582.0130.731, 5.543
    ER-α0.17390.5460.228, 1.306
    PR0.44960.7150.299, 1.708
    CCL5+/ER-α0.17151.8700.762, 4.587
    CCL5+/PR0.56421.2990.534, 3.162
    CCL5/ER-α+0.11090.3040.070, 1.314
    CCL5/PR+0.09170.1770.024, 1.325
  • NOTE: The analysis includes 53 patients at stage I of disease and 89 patients at stage II of disease. Stage II patients were further divided to stage IIA (62 patients) and stage IIB (27 patients).

    Abbreviation: HR, hazard ratio.